Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer
Trial Details
- NCT ID
- NCT05200260
- Phase
- PHASE2
- Sponsor
- Shanghai Gynecologic Oncology Group
- Status
- RECRUITING
- Cancer Type
- Ovarian Cancer
- Interventions
- Primary debulking surgery
- Neoadjuvant chemotherapy
- PARP inhibitor
- Bevacizumab
- Locations (sample)
- Foshan, China|23.02677,113.13148
- Guangzhou, China|23.11667,113.25
- Hangzhou, China|30.29365,120.16142
- Hangzhou, China|30.29365,120.16142
- Hefei, China|31.86389,117.28083
Key Eligibility Criteria
- Females aged ≥ 18 years.
- Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma
- Low, Middle tumor burden and high tumor burden with cPCI score ≤ 12 based on pre-operative CT or PET/CT examination
- Complete cytoreduction can be achieved based on CT or PET/CT examination
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Ovarian Cancer Trials on Trialify →